Assyro Team
20 min read
ICH Guidelines Overview: Complete List of Quality, Safety, and Efficacy Guidelines
Quick Answer
ICH (International Council for Harmonisation) publishes guidelines across four categories — Quality, Safety, Efficacy, and Multidisciplinary. As of March 18, 2026, the current ICH index spans Q1-Q14, S1-S13, E1-E23, and M1-M18, with some numbers grouped, unused, or still under development. The authoritative current listing is maintained on the ICH website.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is the body responsible for creating the technical standards that govern pharmaceutical development worldwide. Established in 1990 as the International Conference on Harmonisation, ICH became a legal entity in 2015 and now includes regulatory agencies and pharmaceutical industry associations from the US, EU, Japan, Canada, Switzerland, Brazil, China, South Korea, Singapore, and other countries.
ICH guidelines eliminate duplicative and conflicting technical requirements across regulatory regions. Before ICH, a pharmaceutical company developing a drug for global markets would need to conduct different studies, use different formats, and meet different standards for each country's regulatory agency. ICH harmonization means that a single set of studies, conducted to ICH standards, is accepted by all member regulatory authorities.
In this guide, you'll learn:
- The ICH organizational structure and guideline development process
- All Quality guidelines (Q1 through Q14) and their scope
- All Safety guidelines (S1 through S12) and their scope
- Key Efficacy guidelines (E1 through E20) and their scope
- Multidisciplinary guidelines (M1 through M14) including the CTD format
- Which guidelines are most critical at each stage of drug development
ICH Organizational Structure
Members and Observers
ICH membership includes both regulatory authorities and industry associations:
| Category | Members |
|---|---|
| Founding Regulatory Members | FDA (US), EMA (EU), PMDA (Japan) |
| Founding Industry Members | PhRMA (US), EFPIA (EU), JPMA (Japan) |
| Regulatory Members (added) | Health Canada, Swissmedic, ANVISA (Brazil), NMPA (China), MFDS (South Korea), HSA (Singapore), TFDA (Chinese Taipei) |
| Standing Regulatory Observers | WHO, EDQM (European Directorate for the Quality of Medicines) |
Guideline Development Process
ICH guidelines progress through a five-step process:
| Step | Activity | Timing |
|---|---|---|
| Step 1 | Concept paper and business plan approved by ICH Assembly; Expert Working Group begins consensus building | Varies by topic |
| Step 2 | Technical consensus and draft guideline adoption for regulatory consultation | Varies by topic |
| Step 3 | Regulatory consultation and discussion of comments | Varies by topic |
| Step 4 | Final guideline adopted by the ICH Assembly | Guideline-specific |
| Step 5 | Implementation by ICH regulatory members and observers | Region-specific |
Guideline Categories
| Category | Code | Focus Area | Current ICH Index |
|---|---|---|---|
| Quality | Q | Manufacturing, quality control, specifications, stability | Q series |
| Safety | S | Nonclinical safety studies | S series |
| Efficacy | E | Clinical trial design, conduct, analysis, and reporting | E series |
| Multidisciplinary | M | Cross-cutting topics such as MedDRA, CTD/eCTD, bioequivalence, and model-informed development | M series |
Quality Guidelines (Q Series)
Quality guidelines govern pharmaceutical manufacturing, quality control, and specifications. They define the technical requirements for CTD Module 3 (Quality).
Q1: Stability Testing
| Guideline | Title | Key Content | Step 4 Date |
|---|---|---|---|
| Q1A(R2) | Stability Testing of New Drug Substances and Drug Products | Storage conditions, testing frequency, study design, photostability, shelf life determination | February 2003 |
| Q1B | Stability Testing: Photostability Testing of New Drug Substances and Drug Products | Photostability study design, ICH light exposure conditions (1.2M lux-hours, 200 W-hr/m2 UV) | November 1996 |
| Q1C | Stability Testing for New Dosage Forms | Reduced stability requirements for new dosage forms of already-approved drug substances | November 1996 |
| Q1D | Bracketing and Matrixing Designs for Stability Testing | Statistical approaches to reduce stability testing burden for multiple strengths/sizes | February 2002 |
| Q1E | Evaluation of Stability Data | Statistical approaches for shelf life estimation, including extrapolation beyond available data | February 2003 |
| Q1F | Stability Data Package for Registration Applications in Climatic Zones III and IV | Originally published 2003; withdrawn 2006 due to disagreement on climatic zone IV conditions | Withdrawn |
“Practical Impact: Q1A(R2) defines the stability conditions (25C/60%RH long-term, 40C/75%RH accelerated) and testing intervals (0, 3, 6, 9, 12, 18, 24, 36 months) that appear in every NDA/MAA quality section. Non-compliance with Q1A stability requirements is one of the most common reasons for Module 3 deficiency findings.
Q2: Analytical Validation
| Guideline | Title | Key Content | Step 4 Date |
|---|---|---|---|
| Q2(R2) | Validation of Analytical Procedures | Validation parameters (accuracy, precision, specificity, linearity, range, LOD, LOQ, robustness), ATP concept | November 2022 |
Q3: Impurities
| Guideline | Title | Key Content | Step 4 Date |
|---|---|---|---|
| Q3A(R2) | Impurities in New Drug Substances | Reporting, identification, and qualification thresholds for organic impurities in drug substances | October 2006 |
| Q3B(R2) | Impurities in New Drug Products | Reporting, identification, and qualification thresholds for degradation products in drug products | June 2006 |
| Q3C(R8) | Impurities: Guideline for Residual Solvents | Classification of solvents (Class 1/2/3), PDE limits, testing requirements | Current: April 2021 |
| Q3D(R2) | Guideline for Elemental Impurities | Classification of 24 elements, PDE limits, risk assessment approach | April 2022 |
| Q3E | Guideline for Extractables and Leachables | Assessment of E&L from container closure systems, manufacturing equipment, and packaging | Under development |
Q4-Q7: Pharmacopeial, Terminology, and GMP
| Guideline | Title | Key Content | Step 4 Date |
|---|---|---|---|
| Q4A | Pharmacopoeial Harmonisation | Harmonization of pharmacopoeial analytical procedures | Ongoing program |
| Q4B | Evaluation and Recommendation of Pharmacopoeial Texts | Interchangeability of pharmacopoeial procedures and standards | November 2007 |
| Q5A(R2) | Viral Safety Evaluation of Biotechnology Products | Viral safety testing strategy for biotech-derived products from cell lines | Under revision (R2 in development); original 1999 |
| Q5B | Analysis of Expression Construct in Cells for Production of rDNA-Derived Proteins | Characterization of expression construct in production cells | November 1995 |
| Q5C | Quality of Biotechnological Products: Stability Testing | Stability testing for biological/biotechnological products (complements Q1A) | November 1995 |
| Q5D | Derivation and Characterisation of Cell Substrates for Biological Products | Cell bank preparation, characterization, testing | July 1997 |
| Q5E | Comparability of Biotechnological/Biological Products Subject to Changes in Manufacturing | Comparability assessment framework for manufacturing changes to biologics | November 2004 |
| Q6A | Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and Drug Products (Chemical Entities) | Decision trees for selecting specifications; universal and specific tests | October 1999 |
| Q6B | Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products | Specification development for biologics | March 1999 |
| Q7 | Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients | GMP requirements for drug substance (API) manufacturing | November 2000 |
Q8-Q14: Development, Risk, Quality System, and Lifecycle
| Guideline | Title | Key Content | Step 4 Date |
|---|---|---|---|
| Q8(R2) | Pharmaceutical Development | QbD framework: QTPP, CQAs, design space, control strategy | August 2009 |
| Q9(R1) | Quality Risk Management | Risk management principles, tools (FMEA, FTA, HACCP), application throughout the quality system | January 2023 (R1) |
| Q10 | Pharmaceutical Quality System | PQS model: CAPA, change management, knowledge management, management review across lifecycle | June 2008 |
| Q11 | Development and Manufacture of Drug Substances | Drug substance development: starting materials, process description, control strategy, impurity fate/purge | November 2012 |
| Q12 | Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management | Established conditions, PACMP, reporting categories for post-approval changes | November 2019 |
| Q13 | Continuous Manufacturing of Drug Substances and Drug Products | Regulatory and technical considerations for continuous manufacturing processes | November 2022 |
| Q14 | Analytical Procedure Development | Analytical procedure lifecycle: ATP, MODR, enhanced development approach | November 2022 |
Safety Guidelines (S1-S12)
Safety guidelines govern nonclinical (preclinical) safety evaluation. They define the studies required before and during clinical development, primarily supporting CTD Module 4 (Nonclinical Study Reports).
Carcinogenicity and Genotoxicity
| Guideline | Title | Key Content | Step 4 Date |
|---|---|---|---|
| S1A | The Need for Long-Term Rodent Carcinogenicity Studies | Criteria for when carcinogenicity studies are required (chronic dosing >6 months, concerning signals) | November 1995 |
| S1B(R1) | Testing for Carcinogenicity of Pharmaceuticals | Revised approach; 2-year rat study or weight of evidence including Tg mouse + supplementary data | July 2022 |
| S1C(R2) | Dose Selection for Carcinogenicity Studies | High dose selection criteria: MTD, 25x human exposure, limit dose, saturation of absorption | July 2008 |
| S2(R1) | Genotoxicity Testing and Data Interpretation | Standard battery (Options 1 and 2), top concentration limits, follow-up strategies, weight of evidence | November 2011 |
General Toxicology
| Guideline | Title | Key Content | Step 4 Date |
|---|---|---|---|
| S3A | Note for Guidance on Toxicokinetics | Toxicokinetic assessment in nonclinical safety studies; exposure-response relationships | October 1994 |
| S3B | Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies | When tissue distribution studies are needed beyond standard ADME | October 1994 |
| S4 | Duration of Chronic Toxicity Testing in Animals | Duration of repeated-dose studies in rodents and non-rodents to support clinical development | September 1998 |
| S5(R3) | Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals | Fertility, embryo-fetal development, pre/postnatal development study designs | February 2020 |
| S6(R1) | Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals | Nonclinical testing strategy for biologics; species selection, immunogenicity, tissue cross-reactivity | June 2011 |
| S7A | Safety Pharmacology Studies for Human Pharmaceuticals | Core battery: cardiovascular, respiratory, CNS safety pharmacology | November 2000 |
| S7B(R1) | Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) | hERG assay, in vivo QT assessment; integrated with E14(R3) | May 2022 |
Specialized Safety Topics
| Guideline | Title | Key Content | Step 4 Date |
|---|---|---|---|
| S8 | Immunotoxicity Studies for Human Pharmaceuticals | When immunotoxicity evaluation is needed; standard toxicity study endpoints; additional studies | September 2005 |
| S9 | Nonclinical Evaluation for Anticancer Pharmaceuticals | Reduced nonclinical requirements for oncology drugs; risk-benefit considerations | October 2009 |
| S10 | Photosafety Evaluation of Pharmaceuticals | Assessment of phototoxic potential; UV/Vis absorption, in vitro 3T3 NRU, in vivo assessment | November 2013 |
| S11 | Nonclinical Safety Testing in Support of Development of Paediatric Pharmaceuticals | When juvenile animal studies are needed; study design for pediatric drug development | January 2020 |
| S12 | Nonclinical Biodistribution Considerations for Gene Therapy Products | Biodistribution study design for gene therapy vectors; shedding studies | July 2023 |
Efficacy Guidelines (E Series)
Efficacy guidelines govern clinical trial design, conduct, and reporting. They support CTD Module 5 (Clinical Study Reports) and the clinical development program overall.
Key Efficacy Guidelines
| Guideline | Title | Key Content | Step 4 Date |
|---|---|---|---|
| E1 | The Extent of Population Exposure to Assess Clinical Safety | Minimum exposure database for NDA/MAA: 1500 patients total, 300-600 for 6 months, 100 for 1 year | October 1994 |
| E2A | Clinical Safety Data Management: Definitions and Standards for Expedited Reporting | Definitions of AE, SAE, unexpected AE; expedited reporting requirements (ICSRs) | October 1994 |
| E2B(R3) | Electronic Transmission of Individual Case Safety Reports (ICSRs) | ICH E2B(R3) format for electronic ICSR submission (E2B XML) | February 2014 |
| E2C(R2) | Periodic Benefit-Risk Evaluation Report (PBRER) | PBRER format replacing PSUR; periodic benefit-risk assessment throughout product lifecycle | November 2012 |
| E2D | Post-Approval Safety Data Management: Definitions and Standards | Post-marketing safety data handling and reporting | November 2003 |
| E2E | Pharmacovigilance Planning | Safety specification, pharmacovigilance plan, risk minimization | November 2004 |
| E2F | Development Safety Update Report (DSUR) | Annual safety report during clinical development (replaces IND annual safety report) | August 2010 |
| E3 | Structure and Content of Clinical Study Reports | CSR format and content requirements; 16 sections | November 1995 |
| E5(R1) | Ethnic Factors in the Acceptability of Foreign Clinical Data | Framework for evaluating whether foreign clinical data can support regional registration | February 1998 |
| E6(R2) | Good Clinical Practice | GCP requirements; investigator, sponsor, IRB/IEC responsibilities; risk-based monitoring | November 2016 |
| E7 | Studies in Support of Special Populations: Geriatrics | Requirements for geriatric inclusion in clinical programs | June 1993 |
| E8(R1) | General Considerations for Clinical Studies | Overall clinical development planning; quality by design for clinical studies | October 2021 |
| E9(R1) | Statistical Principles for Clinical Trials | Statistical design, conduct, analysis, and reporting; addendum on estimands | November 2019 (R1 addendum) |
| E10 | Choice of Control Group in Clinical Trials | Placebo, active control, dose-response, external control; assay sensitivity | July 2000 |
| E11A | Pediatric Extrapolation | Framework for extrapolating adult efficacy/safety data to pediatric populations | August 2022 |
| E12 | Clinical Evaluation by Therapeutic Category (series) | Disease-specific guidelines (allergy, cardiovascular, etc.) | Various |
| E14(R3) | Clinical Evaluation of QT/QTc Interval Prolongation | Clinical QT assessment; concentration-QT analysis; integrated with S7B(R1) | May 2022 |
| E15 | Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding | Standard terminology for genomic biomarkers in drug development | November 2007 |
| E16 | Biomarkers Related to Drug or Biotechnology Product Development | Qualification of biomarkers for regulatory decision-making | August 2010 |
| E17 | General Principles for Planning and Design of Multi-Regional Clinical Trials | Design principles for MRCTs; consistency of treatment effect across regions | November 2017 |
| E18 | Genomic Sampling and Management of Genomic Data | Collection, analysis, and reporting of genomic data in clinical trials | September 2017 |
| E19 | Optimization of Safety Data Collection | Risk-based approach to safety data collection in clinical trials | November 2019 |
| E20 | Adaptive Clinical Trials | Design, conduct, and statistical analysis of adaptive clinical trials | Under development |
Multidisciplinary Guidelines (M Series)
Multidisciplinary guidelines span multiple ICH categories and address cross-cutting topics.
| Guideline | Title | Key Content | Step 4 Date |
|---|---|---|---|
| M1 | MedDRA (Medical Dictionary for Regulatory Activities) | Standardized medical terminology for regulatory communication | Ongoing |
| M2 | Electronic Standards for the Transfer of Regulatory Information (ESTRI) | Electronic submission standards; eCTD gateway specifications | Ongoing |
| M3(R2) | Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials | Timing of nonclinical studies relative to clinical development phases | June 2009 |
| M4 (M4Q, M4S, M4E) | Organisation of the CTD | CTD structure: Module 1 (Regional), Module 2 (Summaries), Module 3 (Quality), Module 4 (Nonclinical), Module 5 (Clinical) | Various (Q: 2002, S: 2002, E: 2002) |
| M5 | Data Elements and Standards for Drug Dictionaries | Standardized drug dictionary elements | May 2004 |
| M7(R1) | Assessment and Control of DNA Reactive (Mutagenic) Impurities | Mutagenic impurity assessment, TTC-based limits, class structure-based evaluation, purge factor approach | March 2017; R2 in development |
| M8 | eCTD | Electronic CTD format specifications (v3.2.2, v4.0) | Various |
| M9 | Biopharmaceutics Classification System-Based Biowaivers | BCS classification criteria; biowaiver eligibility for BCS Class I and III compounds | November 2019 |
| M10 | Bioanalytical Method Validation and Study Sample Analysis | Validation of bioanalytical methods (PK, biomarker); study sample analysis requirements | May 2022 |
| M11 | Clinical Electronic Structured Harmonised Protocol (CeSHarP) | Standardized electronic clinical trial protocol format | Under development |
| M12 | Drug Interaction Studies | Comprehensive guidance on drug-drug interaction studies (in vitro and clinical) | May 2024 |
| M13 | Bioequivalence for Immediate-Release Solid Oral Dosage Forms | Harmonized bioequivalence study design and acceptance criteria | Under development |
| M14 | Use of real-world data for safety assessment of medicines | Framework for using real-world data in safety assessment | Under development |
| M15 | General Principles for Model-Informed Drug Development | Core principles for model-informed development and regulatory use | Under development |
| M16 | Structured Product Quality Submissions | Structured quality submission concepts and standards | Under development |
| M18 | Framework for Determining the Utility of Comparative Efficacy Studies in Biosimilar Development Programs | Framework for when comparative efficacy studies are useful in biosimilar programs | Under development |
Most Critical Guidelines by Development Stage
IND-Enabling (Pre-Clinical)
| Guideline | Why Critical |
|---|---|
| M3(R2) | Determines timing of all nonclinical studies |
| S2(R1) | Genotoxicity battery required before Phase 1 |
| S7A | Core safety pharmacology battery required before Phase 1 |
| S7B(R1) | hERG and in vivo QT assessment |
| Q3A(R2) | Impurity qualification thresholds for drug substance |
| Q1A(R2) | Stability data requirements for clinical material |
| M7(R1) | Mutagenic impurity control in clinical material |
Phase 1-3 (Clinical Development)
| Guideline | Why Critical |
|---|---|
| E6(R2) | GCP compliance for all clinical trials |
| E2A | Safety reporting definitions and requirements |
| E2F | DSUR (annual safety reporting during development) |
| E8(R1) | Clinical development planning |
| E9(R1) | Statistical design and analysis |
| E14(R3) | QT assessment strategy |
| Q1A(R2) | Ongoing stability for clinical material and registration batches |
NDA/MAA Filing
| Guideline | Why Critical |
|---|---|
| M4 (Q, S, E) | CTD format and organization for the entire dossier |
| M8 | eCTD electronic submission format |
| Q6A/Q6B | Specification setting for drug substance and product |
| Q3A/Q3B/Q3C/Q3D | Impurity control strategy |
| Q8(R2) | Pharmaceutical development documentation |
| Q11 | Drug substance development documentation |
| E3 | Clinical study report format |
| S1B(R1) | Carcinogenicity study (if required) |
Post-Approval (Commercial)
| Guideline | Why Critical |
|---|---|
| Q10 | Pharmaceutical quality system for commercial manufacturing |
| Q12 | Post-approval change management |
| Q1A(R2) | Ongoing stability program |
| E2C(R2) | PBRER for periodic safety assessment |
| Q9(R1) | Risk management throughout commercial operations |
Recent and Upcoming ICH Developments
Recently Adopted (2022-2024)
| Guideline | Status | Key Change |
|---|---|---|
| Q2(R2) | Adopted November 2022 | ATP concept, multivariate methods, lifecycle approach |
| Q9(R1) | Adopted January 2023 | Risk-based decision-making, formality of risk management |
| Q13 | Adopted November 2022 | Continuous manufacturing regulatory framework |
| Q14 | Adopted November 2022 | Analytical procedure development, MODR concept |
| S1B(R1) | Adopted July 2022 | Weight-of-evidence approach may replace 2-year bioassay |
| S7B(R1) / E14(R3) | Adopted May 2022 | Integrated nonclinical-clinical QT assessment |
| M10 | Adopted May 2022 | Harmonized bioanalytical method validation |
| M12 | Adopted May 2024 | Comprehensive drug interaction studies guidance |
| S12 | Adopted July 2023 | Gene therapy biodistribution |
Under Development (as of 2026)
| Guideline | Stage | Expected Focus |
|---|---|---|
| E6(R3) | Step 2b (draft) | Modernized GCP for decentralized trials, digital data |
| Q3E | Development | Extractables and leachables |
| Q5A(R2) | Development | Updated viral safety evaluation |
| M7(R2) | Development | Updated mutagenic impurities guidance |
| M11 | Development | Electronic clinical protocol format |
| M13 | Development | Harmonized bioequivalence |
| M14 | Development | Real-world evidence framework |
| E20 | Development | Adaptive clinical trial design |
Key Takeaways
References
ICH guidelines themselves are not legally binding. They are recommendations. However, when adopted by a regulatory authority (FDA, EMA, PMDA), they become the expected standard. FDA adopts ICH guidelines as "Guidance for Industry" documents, which represent the agency's current thinking. While not strictly mandatory, deviations from ICH guidance require scientific justification and may trigger reviewer questions.